EASD 2020 — T2D: real-world cardiovascular outcomes of SGLT2 inhibitors vs GLP-1 receptor agonists

  • Suresh Palle
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • In patients with type 2 diabetes (T2D), sodium-glucose co-transporter-2 inhibitors (SGLT2i) may be more effective than glucagon-like peptide-1 receptor agonists (GLP-1RA) in improving cardiovascular outcomes.

Why this matters

  • In absence of dedicated trials, evidence from this real-world observational study could serve as moderate evidence to guide the best treatment choice for reduced cardiovascular risk in patients with T2D.

Study design

  • This retrospective study included 12,996 patients (mean age, 63 years) with T2D who initiated SGLT2i or GLP-1RA between 2014 and 2018.
  • SGLT2i (n=4298) and GLP-1RA (n=4298) users were matched 1:1 using propensity score matching.
  • Cardiovascular outcomes evaluated were a composite of all-cause death, myocardial infarction (MI) and stroke (3-point major adverse cardiovascular events [3P-MACE]); hospitalization for heart failure (HHF); revascularization; and hospitalization for cardiovascular diseases (CVD).
  • Funding: None.

Key results

  • GLP-1RA reduced HbA1c more than SGLT2i, whereas SGLT2i improved systolic blood pressure and high-density lipoprotein cholesterol better than GLP-1RA.
  • In ‘as-treated’ analysis, SGLT2i vs GLP-1RA significantly reduced risk for:
    • 3P-MACE: HR, 0.78; 95% CI, 0.61-0.99; P=.043;
    • HHF: HR, 0.59; 95% CI, 0.35-0.99; P=.048; and
    • hospitalization for CVD: HR, 0.82; 95% CI, 0.69-0.99; P=.037.
  • Among 3P-MACE components, the strongest difference between the 2 groups was found for MI (HR, 0.72; 95% CI, 0.53-0.98; P=.035).
  • Results were similar in intention-to-treat analysis:
    • 3P-MACE: HR, 0.78; 95% CI, 0.62-0.97; P=.027; and
    • MI: HR, 0.75; 95% CI, 0.56-0.98; P=.039.
  • SGLT2i vs GLP-1RA was associated with lower rates of 3P-MACE among patients with baseline CVD (HR, 0.70; 95% CI, 0.49-0.99; P=.049) and lower HHF rates among patients without CVD (HR, 0.39; 95% CI, 0.15-0.99; P=.048).
  • Overall, adverse events were not significantly different between the 2 groups, but a trend towards lower risk for renal events was found with SGLT2i vs GLP-1RA (acute kidney injury: HR, 0.55; 95% CI, 0.28-1.09; P=.086).


  • Retrospective design.
  • Laboratory values were available only for a subset of patients.